Pancreatic Cancer Research

ResearcherTeikyo UniversityActive in the last 2 years

Keiji Sano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5435-9276; OpenAlex author ID A5045601646. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2013: 3 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 10

  1. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  2. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  3. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  4. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk panc… Last author DOI 10.1002/jhbp.601↗
  5. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcino… Last author DOI 10.1002/jhbp.524↗
  6. Diffusion-weighted MR imaging of pancreatic cancer and inflammation: Prognostic significance of pancreatic inflammation in pancreatic cancer patients. Co-author DOI 10.1016/j.pan.2015.10.004↗
  7. Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study. First author DOI 10.1002/jhbp.274↗
  8. Correlation of apparent diffusion coefficient measured by diffusion-weighted MRI and clinicopathologic features in pancreatic cancer patients. Co-author DOI 10.1007/s00534-011-0491-5↗
  9. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. Co-author DOI 10.1007/s00534-013-0611-5↗
  10. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments:… Co-author DOI 10.1007/s00534-013-0616-0↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keita Wada · 7 shared papers, 2013–2019 · strength 0.38
  2. Naoya Kato · 2 shared papers, 2023–2024 · strength 0.29
  3. Satoshi Kobayashi · 2 shared papers, 2023–2024 · strength 0.29
  4. Masafumi Ikeda · 2 shared papers, 2023–2024 · strength 0.29
  5. Masato Ozaka · 2 shared papers, 2023–2024 · strength 0.29
  6. Junji Furuse · 2 shared papers, 2023–2024 · strength 0.29
  7. Makoto Ueno · 2 shared papers, 2023–2024 · strength 0.29
  8. Sachiyo Kawamura · 2 shared papers, 2018–2019 · strength 0.18
  9. Hisae Iinuma · 2 shared papers, 2018–2019 · strength 0.18
  10. Takeshi Terashima · 1 shared paper, 2024 · strength 0.17
  11. Kohei Nakachi · 1 shared paper, 2024 · strength 0.17
  12. Hiroshi Imaoka · 1 shared paper, 2024 · strength 0.17
  13. Shun Tezuka · 1 shared paper, 2024 · strength 0.17
  14. Michiaki Unno · 1 shared paper, 2024 · strength 0.17
  15. Chigusa Morizane · 1 shared paper, 2024 · strength 0.17
  16. Kentaro Sudo · 1 shared paper, 2023 · strength 0.12
  17. Satoaki Nakamura · 1 shared paper, 2023 · strength 0.12
  18. Toshio Nakagohri · 1 shared paper, 2023 · strength 0.12
  19. Nobumasa Mizuno · 1 shared paper, 2023 · strength 0.12
  20. Tatsuya Ioka · 1 shared paper, 2023 · strength 0.12
  21. Hiroshi Ishii · 1 shared paper, 2023 · strength 0.12
  22. Naohiro Okano · 1 shared paper, 2023 · strength 0.12
  23. Ryoji Takada · 1 shared paper, 2023 · strength 0.12
  24. Kunihito Gotoh · 1 shared paper, 2023 · strength 0.12
  25. Akiko Todaka · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.